To use all functions of this page, please activate cookies in your browser.
BioMCN to produce renewable methanol with green hydrogen
Nouryon (formerly AkzoNobel Specialty Chemicals) and Gasunie have agreed to supply green hydrogen to BioMCN for the production of renewable methanol from CO2. The companies say it marks the next step in the sustainability of processes in the industry.
Nouryon and Gasunie are currently investigating the possible conversion of sustainable electricity into green hydrogen using a 20-megawatt water electrolysis unit in Delfzijl, the Netherlands. A final decision on the project is expected later this year.
BioMCN will combine hydrogen from the intended facility with CO2 from other processes to produce renewable methanol, a raw material for bio-fuels and a variety of chemical feedstocks. Compared to fossil-based methanol this will reduce emissions by up to 27,000 tons of CO2 per year.
Søren Jacobsen, Managing Director at BioMCN said: “This partnership is an important step towards a circular economy. Thanks to the supply of green hydrogen, we can replace natural gas as a feedstock and recycle carbon emissions to produce new raw materials and fuels, effectively turning CO2 emissions into carbon savings and helping the Netherlands meet its carbon reduction goals.”
Knut Schwalenberg, Managing Director Industrial Chemicals at Nouryon added: “Green hydrogen is a realistic alternative for fossil-based raw materials and enables new forms of green chemistry. This agreement will help to support long-term growth in that market.”
Gerard van Pijkeren, Managing Director at Gasunie New Energy said: “Gas infrastructure plays a connecting and facilitating role in the energy transition. We will be transporting different energy carriers, such as hydrogen and green gas, increasingly through our pipelines in the future. As independent network operator we can connect hydrogen from different suppliers for transportation to the major industrial clusters in the Netherlands. This network may have a capacity of 10 gigawatts or more by 2030.”
- 1Scientists discover potential cause of Alzheimer’s Disease
- 2Only alcohol -- not caffeine, diet or lack of sleep -- might trigger heart rhythm condition
- 3Insect wings inspire new ways to fight superbugs
- 4Reducing side effects during the treatment of brain tumours
- 5Aerogel – the micro structural material of the future
- 6Eppendorf AG records strong first half-year 2020
- 7How antibiotics interact
- 8New insights into lung tissue in Covid-19 disease
- 9Coronavirus SARS-CoV-2 spreads more indoors at low humidity
- 10From Biopaste to Bioplastic
- The genes behind the venom: New technique revolutionizes venom research
- EMA starts rolling review of COVID-19 vaccine Vidprevtyn
- Machine learning helps in predicting when immunotherapy will be effective
- VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders
- Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands